Biogen’s Alzheimer’s drug Aduhelm
Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved
The real-world findings support the long-term benefits of continuous treatment
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Teva submits FDA application for paediatric Tourette syndrome therapy
Ecopipam could become the first new FDA-approved treatment for paediatric Tourette syndrome in over ten years
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
Biogen to acquire RayThera in $1bn deal
The acquisition will expand the company’s immunology pipeline
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer
Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA
In the study, there were improvements in motor function as well as a slowing of neurodegeneration
FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders
The mortality rates of UCDs exceeds 25%, with no curative treatment available for newborns
Biogen agrees $850m felzartamab rights deal with TJ Biopharma
The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases
MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment
SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK